Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
Intravenous (IV) ketamine is effective in adults resistant to depression. The response was similar to that seen in younger patients, two new studies show.
Read Full NewsResearch reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.
The REVISE trial, a phase 2 study evaluating GenSight Biologics’ lenadogene nolparvovec in patients with Leber hereditary optic neuropathy, is expected to begin in January 2026.
Intellia’s trial for nex-z in ATTR-CM remains under clinical hold.
Arai breaks down key recommendations from the 2025 AGA gastroparesis guidelines and what they mean for the field at large.
IMMpactful: Risankizumab Shows Greater Clinical Response to Deucravacitinib in Psoriasis
1.
For elderly, unfit patients, the all-oral AML regimen shows promise.
2.
Adaptive SABR-Used Hypofractionated Chemoradiation Showed Good Results in NSCLC.
3.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
4.
Experts Debate AQUILA Trial Findings in Smoldering Multiple Myeloma
5.
The discovery of drug combinations may increase the life expectancy of children with brain cancer.
1.
Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training
2.
Early Detection of Breast Cancer: Signs, Symptoms, and Screening Methods
3.
Uncovering the Hidden Signs: How to Recognize the Early Symptoms of Colon Cancer
4.
Cracking the Code of Subdural Hematomas: Modern Strategies for Optimal Care
5.
Unlocking the Secrets of Ringed Sideroblasts: A New Frontier in Hematology
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Oropharyngeal Cancer in Relation to HPV Status
4.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
5.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge